Revenue
2018
2022
2023
2024
2025
Neurogene Inc. (NGNE)
Price$37.88Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $925,000 | $0 | $0 | — | — | — | $25.0M | — | — | — | — | — | — |
| Research & development | $75.0M | $60.9M | $44.4M | $47.5M | $39.2M | $24.3M | $4.4M | $41.8M | $36.3M | $28.4M | $15.8M | $18.1M | $7.6M | $6.0M |
| Operating expenses | $103.3M | $83.5M | $55.6M | $56.5M | $60.7M | — | $71.0M | $57.6M | $51.1M | $37.6M | $21.3M | $22.4M | $9.4M | $7.7M |
| Operating income | −$103.3M | −$82.6M | −$55.6M | −$56.5M | −$60.7M | −$33.7M | −$71.0M | −$32.6M | −$51.1M | −$37.6M | — | — | — | — |
| Operating margin | — | −8,930.27% | — | — | — | — | — | −130.50% | — | — | — | — | — | — |
| EBITDA | −$100.3M | −$79.4M | −$52.3M | −$53.3M | −$59.4M | −$32.9M | −$70.6M | −$32.3M | −$50.8M | — | — | — | — | — |
| EBITDA margin | — | −8,584.86% | — | — | — | — | — | −129.34% | — | — | — | — | — | — |
| Net income | −$90.4M | −$75.1M | −$36.3M | −$55.2M | −$60.7M | −$33.3M | −$69.4M | −$31.6M | −$50.2M | −$37.0M | −$21.9M | −$24.0M | −$8.7M | −$7.7M |
| Net profit margin | — | −8,123.68% | — | — | — | — | — | −126.34% | — | — | — | — | — | — |
| Basic EPSper basic share | -$4.24 | -$4.28 | -$73.84 | -$20.80 | -$22.00 | -$12.80 | -$51.40 | -$26.80 | -$42.80 | -$39.20 | -$34.60 | -$55.00 | -$990.40 | -$804.60 |
| Diluted EPSper diluted share | -$4.24 | -$4.28 | -$73.84 | -$20.80 | -$22.00 | -$12.80 | -$51.40 | -$26.80 | -$42.80 | -$39.20 | -$34.60 | -$55.00 | -$990.40 | -$804.60 |
Owners
Reported shareholders
≈10.85%of listed shares
AKKARAJU SRINIVAS / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC1.72M shares · Nov 26, 2024
View holders
| Holder | % owned |
|---|---|
AKKARAJU SRINIVAS / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC | ≈10.85%1.72M shares |
SAMSARA BIOCAPITAL, LLC | 10.85%1.72M shares |
Casdin Capital, LLC | 9.76%1.55M shares |
Redmile Group, LLC | 8.92%1.41M shares |
RTW INVESTMENTS, LP | 8.61%1.36M shares |
McMinn Rachel | ≈8.49%1.34M shares |
EcoR1 Capital, LLC | 8.03%1.27M shares |
BlackRock, Inc. | 6.68%1.06M shares |
BAKER BROS. ADVISORS LP | 6.26%991.69K shares |
Balyasny Asset Management L.P. | 5.17%818.71K shares |
Trails Edge Capital Partners, LP | 4.52%714.89K shares |
TORONTO DOMINION BANK | 4.30%681.34K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.39%536.53K shares |
JENNISON ASSOCIATES LLC | 3.28%518.58K shares |
CITADEL ADVISORS LLC | 2.58%408.98K shares |
GREAT POINT PARTNERS LLC | 2.22%352.18K shares |
ArrowMark Colorado Holdings LLC | 2.16%342.45K shares |
FMR LLC | 1.87%295.56K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.85%293.18K shares |
STATE STREET CORP | 1.42%224.32K shares |
Percentages use 15.83M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 6, 2026Form 4 · 10b5-1 | Cvijic Christine MikailPresident and CFO | SellCommon Stock | 4.8K | $32.44 | $155.7K | 93.6K |
| May 6, 2026Form 4 · 10b5-1 | Cvijic Christine MikailPresident and CFO | SellCommon Stock | 4.8K | $30.07 | $144.3K | 98.4K |
| Mar 26, 2026Form 4 · 10b5-1 | Jordan JulieChief Medical Officer | SellCommon Stock | 828 | $21.89 | $18.1K | 12.5K |
| Mar 26, 2026Form 4 · 10b5-1 | McMinn RachelChief Executive Officer | SellCommon Stock | 3.4K | $22.07 | $74.0K | 1.34M |
| Mar 26, 2026Form 4 · 10b5-1 | Cvijic Christine MikailPresident and CFO | SellCommon Stock | 2.6K | $21.62 | $55.3K | 103.2K |